Skip to main content
SRTS logo

SRTS · Sensus Healthcare, Inc.

Track SRTS — free
$2.36 +0.06 (+2.61%) At close · Nov 19
Market Cap
$38.85M
Shares
16.46M
Volume · Nov 19 170.43K Avg daily vol (3M) 205.66K

Price & Indicators

 

Key stats

Close
$2.36
Open
$2.30
Day range
$2.30–2.51
52-week closing range
$2.26–5.30
Average volume, 30 days
404K
Short interest
222K · 1.4% of shares · 7.2 days
Short volume, last session
38%
Last earnings
Nov 12, 2026
Latest filing
10-Q · Nov 13
Price history
Jan 2020 to Nov 2026

Up next

Feb 11, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Nine-month revenue falls 48.0% as cash drops to $12.9 million

Sensus Healthcare, Inc. reported revenue of $11.7 million for the nine months ended September 30, 2026, down 48.0%, and a net loss of $12.9 million. Cash fell to $12.9 million from $22.1 million, with no borrowings outstanding.

Revenue $6M ▼ 12.9% Net loss $1.49M Diluted EPS -$0.09
Read from the MD&A section
5 source passages
Sensus Healthcare, Inc. (together with its subsidiaries, Sensus Medical Devices Ltd. and Sensus Healthcare Services, LLC, unless the context otherwise indicates, “Sensus,” “we,” “us,” “our,” or the “Company”) is a medical device company committed to providing highly effective, non-invasive treatments for non-melanoma skin cancer and post-surgical keloid scar prevention. Revenues were $11.7 million for the nine months ended September 30, 2026 compared to $22.5 million for the nine months ended September 30, 2025, a decrease of $10.8 million, or 48.0%. Net cash used in operating activities was $9.1 million for the nine months ended September 30, 2026, consisting of net loss of $12.9 million and an increase in net operating assets of $1.2 million, offset by non-cash activity of $5.0 million. Cash, restricted cash, and cash equivalents were $12.9 million at September 30, 2026 compared to $22.1 million at December 31, 2025, a decrease of $9.2 million. There were no borrowings outstanding under the revolving line of credit with City National Bank of Florida at September 30, 2026 or under the Company’s former revolving line of credit with Fifth Third at December 31, 2025. Open the document at this passage
Nov 12
Earnings call
Shipments and gross margin rise despite revenue decline

Sensus Healthcare, Inc. reported third-quarter revenue of $6 million, down from $6.9 million, while shipments rose to 26 systems from 16 and gross margin improved to approximately 55% from 39%; adjusted EBITDA was negative $1.5 million versus negative $2.4 million.

4 source passages
Revenue was $6 million compared with $6.9 million in the third quarter of 2025, a decline of 13%. We shipped 26 systems in the third quarter compared with 16 a year ago. Gross profit increased to $3.3 million from $2.7 million, and gross margin improved to approximately 55% from 39% a year ago. Adjusted EBITDA was negative $1.5 million versus a negative $2.4 million a year ago. Open the document at this passage
Nov 12
Current report 8-K
Revenue falls as gross margin rises to 55%

Sensus Healthcare reported third-quarter 2026 revenue of $6.0 million, down from $6.9 million, while gross margin improved to 55% from 39.1%. It shipped 26 systems and posted a net loss of $1.5 million.

Financial results
5 source passages
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended September 30, 2026. Revenues of $6.0 million compared with $6.9 million in the third quarter of 2025, reflecting a product mix of lower-priced SRT-100 systems and the absence of sales to a historically large customer. Gross profit increased to $3.3 million from $2.7 million in the third quarter of 2025 and gross margin improved to 55% from 39.1% in the prior-year period. Shipped 26 systems, including eight carried over from the second quarter of 2026 due to financing approval timing, compared with 16 in the prior-year period. Net loss was $1.5 million, or $0.09 per share, compared with net loss of $0.9 million, or $0.06 per share, for the three months ended September 30, 2025. Open the document at this passage
Aug 14
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $2.29M ▼ 68.7% Net loss $8.75M Diluted EPS -$0.53
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$16.62M
Trailing 12 months
Net income (TTM)
−$16.04M
Trailing 12 months
Revenue growth YoY
-12.9%
Year over year
Operating margin
-74.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-29.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$12.92M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.9%
Year over year · more shares
Price change (1Y)
-41.6%
Trailing year
Short interest
1.4%
Latest settlement · 7.2 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 12, 2026
Q3 FY26

TL;DR. Shipments increased to 26 systems, gross margin expanded to 55%, and adjusted EBITDA improved, while third-quarter revenue and net loss declined. Cash also fell, nine-month losses widened, and some shipment revenue was deferred under Fair Deal and rental arrangements.

Bullish
  • + Shipments increased year-over-year to 26 systems from 16.
  • + Gross profit increased to $3.3 million from $2.7 million, and gross margin improved to 55% from 39.1%.
  • + Adjusted EBITDA improved to negative $1.5 million from negative $2.4 million.
  • + The company secured initial system purchases from two large private equity-backed dermatology groups.
  • + The company subsequently placed its 1,000th SRT system.
  • + Management expects the CMS-proposed 26% increase to take effect in 2027.
Bearish
  • − Third-quarter revenue declined 13.0% to $6.0 million from $6.9 million.
  • − Third-quarter net loss widened to $1.5 million, or $0.09 per share, from $0.9 million, or $0.06 per share.
  • − Cash, restricted cash and cash equivalents declined to $12.9 million from $15.2 million at June 30, 2026.
  • − General and administrative expense increased 21.1% to $2.3 million from $1.9 million.
  • − Revenue from three systems shipped under the Fair Deal Agreement program and rental arrangements was deferred over the agreement terms.
  • − Nine-month net loss increased to $12.868 million from $4.552 million.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −30%
below
Price vs 50-day avg −19%
below
RSI (14) 38
neutral
MACD trend Negative
52-week position 3%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −18%
trailing
6-month return −17%
trailing
YTD return −41%
this year
Relative strength −12%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +4 funds added
Insider flow Accumulating
Net +$665.3K over 90 days · 0% sells
Short interest Falling
1.35% of shares out · ▼ -3.3% MoM · 7.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
39 holders — near 3-yr low, contrarian setup
Squeeze score 43
elevated · 0–100
Fundamentals
Strong
Revenue growth −34%
Y/Y
Gross margin 43%
contracting
EPS growth −215%
Y/Y
Free cash flow $332.0K
Balance sheet $22.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 69%
annualized · 1-yr
Max drawdown −57%
past year
ATR 14.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Aug 6, 2020
next 12 months
Revenues $1M
going forward
G&A expense $1.1M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−30% Bearish
Price vs 50-day avg
−19% Bearish
RSI (14)
38 Neutral
MACD trend
Negative Bearish
52-week position
3% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +4 funds added
Insider flow Accumulating
Net +$665.3K over 90 days · 0% sells
Short interest Falling
1.35% of shares out · ▼ -3.3% MoM · 7.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
39 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $2 Now $2 · 3% Range high $5
vs 200-day avg -30% vs 50-day avg -19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Systems shipped under Fair Deal Agreement and rental arrangements 3 the three months ended September 30, 2026 filing —
Adjusted EBITDA, non-GAAP non-GAAP -8.69M Nine Months Ended September 30, 2026 —
Unit shipments 26 third quarter of 2026 —
Active website users 153% Q2 2026 —
Adjusted EBITDA non-GAAP $3M Q2 2026 —
GAAP → non-GAAP reconciliation
GAAP Net loss -8.75M
+86K Depreciation
+70K Stock compensation expense
+5.69M Income tax expense (benefit)
-117K Interest income, net
= Adjusted EBITDA -3.02M

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SRTS
Sensus Healthcare, Inc.
this stock
$38.85M -40.7% -34.3% — 1.4%
ABT
Abbott Laboratories
$179.90B -17.1% +5.7% 38.8 1.1%
MDT
Medtronic plc
$128.69B +4.7% +8.4% 24.8 1.8%
SYK
Stryker Corp
$119.19B -10.9% +11.2% 33.3 1.7%
BSX
Boston Scientific Corp
$62.31B -54.9% +12.5% 18.2 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
39
% held
21.9%
Net QoQ
-37.0K sh
Top holder
Pacific Ridge Capital Par…
Held Float
View
Held by Funds
Fund positions
30
View
Short & Settlement
Short Interest Falling
Shares short
222.3K
Days to cover
7.2d
Change
-7.6K sh
View
Short Volume
Short vol %
38%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
346
Value
$1.0K
As of
Oct 1, 2026
View
Off-Exchange
Off-exchange %
57.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Cluster buy
Net (90d)
+$665.3K
Buyers / Sellers
3 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$27.5M
Net income (FY)
$-7.7M
EPS diluted
$-0.47
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 13, 2026
This year
14

Sensus Healthcare, Inc. reported revenue of $11.7 million for the nine months ended September 30, 2026, down 48.0%, and a net loss of $12.9 million. Cash fell to $12.9 million from $22.1 million, with no borrowings outstanding.

View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Sensus Healthcare Reports Third Q…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
SRTS -26.7% -17.8% -17.2% -14.5% -40.7%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -21.3% -11.5% -11.6% -9.2% -45.7%
Key facts CIK 1494891 CUSIP 81728J109 13F (30d) 42 filings 36 filers Visit website Investor relations